December 2019—The FDA granted breakthrough therapy designation to Novartis’ capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
Read More »Home >> Tag Archives: Novartis
FDA expands use of Novartis’ Kisqali
September 2018—Novartis announced FDA approval for Kisqali (ribociclib) for women with hormone-receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.
Read More »